<DOC>
	<DOCNO>NCT01893151</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Iguratimod versus placebo synovial inflammation , bone erosion bone edema measure MRI wrist Metacarpophalangeal joint patient early Rheumatoid Arthritis ( RA ) .</brief_summary>
	<brief_title>Effectiveness Iguratimod Versus Placebo Treat Early Rheumatoid Arthritis MRI</brief_title>
	<detailed_description>Magnetic resonance imaging ( MRI ) powerful image modality widely use scientific research clinical setting visualise joint patient RA . MRI able image structural damage soft tissue change , ie , synovitis , bone oedema , damage cartilage bone , well tendon pathology . MRI responsive change joint damage use monitor disease progression . In studly , MRI dominant wrist perform baseline ,24 week 52 week , use 1.5T 3.0T MRI dedicate high-resolution wrist phase array coil.The scanner wrist coil use three examination . The hand place wrist coil patient 's side coil anchor base tray reduce motion artefact . The MRI sequence study include OMERACT recommend MRI core set sequence .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Subjects diagnosis RA accord diagnostic criterion American College Rheumatology ( ACR ) ( revised 1987 ) Rheumatoid Arthritis 3 month 2 year time initial diagnosis Functional Class IIIII Subjects active RA time screen Must negative Pregnancy test use adequate method contraception throughout trial Must least 4 tender joint 4 swollen joint ( involve DAS28 ) among , least one swollen Metacarpophalangeal joint essential Has Creactive protein ≥ 10 mg/L OR Erythrocyte Sedimentation Rate ( ESR ) ≥ 28 mm/hr Written inform consent Preceding treatment DMARDs , immunosuppressant ( cyclophosphamide , cyclosporine , azathioprine , etc . ) , biological agent tripterygium within 12 week prior study entry Chest xray abnormality , tuberculosis , interstitial pulmonary fibrosis , etc ALT &gt; 1.5×ULN , AST &gt; 1.5×ULN , Cr &gt; 135umol/L Cr &gt; 1.5mg WBC &lt; 4×109/L，HGB &lt; 85g/L，PLT &lt; 100×109/L Subjects serious cardiovascular , renal , hematologic , endocrine disease malignant Subjects immunodeficiency , uncontrolled infection active gastrointestinal disease Pregnant , intend become pregnant , breastfeeding Subjects rheumatological disease SLE , mixed connective tissue disease , scleroderma , polymyositis , etc Subjects inflammatory arthritis , gout , reactive arthritis , psoriatic arthritis , seronegative spondyloarthropathy , Lyme disease Subjects intraarticular corticosteroid injection within 6 week prior study entry Allergic study drug History alcoholism Subjects mental illness Subjects receive live vaccine recently Subjects participate clinical study within 3 month prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Iguratimod</keyword>
	<keyword>MRI</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>